Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.72 |
| ▸ | ODC1 | P11926 | 2/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.72 |
| ▸ | BACE1 | P56817 | 1/20 | 0.72 |
| ▸ | HIF1AN | Q9NWT6 | 8/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lespeol SCHEMBL5522457 | 0.90 | PTPN1 (0.69) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL19960679 | 0.84 | PTPN1 (1.00) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL31376263 | 0.84 | PTPN1 (1.00) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL29435864 | 0.82 | PTPN1 (0.58) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL16259002 | 0.81 | PDPK1 (0.56) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL19960678 | 0.76 | PTPN1 (0.85) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL31376191 | 0.75 | PTPN1 (0.83) | PTPN1ACHEODC1BCHEBACE1 | |
| Lonchocarpin SCHEMBL29435870 | 0.75 | PTPN1 (0.83) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL29775511 | 0.75 | PTPN1 (0.51) | PTPN1ACHEODC1BCHEBACE1 | |
| SCHEMBL13534952 | 0.74 | ACHE (1.00) | PTPN1ACHEODC1BCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | claimed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | claimed |
| CN-119074703-A | Application of chalcone compounds in preparation of anti-ischemic cerebral apoplexy drugs | 暨南大学 | 2024-12-06 | — | — | CN | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| CN-1816328-A | Therapeutic agent | TAKARA BIO INC (JP) | 2006-08-09 | — | — | CN | disclosed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070092551-A1 | Therapeutic agent | FABP4, GPR119, IAPP | PTPN1 1950/4885ACHE 3384/4885ODC1 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.